Merck, Addex Sign $700 Million Deal For Novel Schizophrenia Candidate
Firms collaborate to develop a metabotropic glutamate receptor 5 target, a possible pathway for treatment of schizophrenia.
Firms collaborate to develop a metabotropic glutamate receptor 5 target, a possible pathway for treatment of schizophrenia.